Skip Navigation


Journal of the National Cancer Institute Advance Access originally published online on July 10, 2007
JNCI Journal of the National Cancer Institute 2007 99(14):1068-1069; doi:10.1093/jnci/djm073
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
99/14/1068    most recent
djm073v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Request Permissions
Google Scholar
Right arrow Articles by Beckman, M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Beckman, M.
Related Collections
Right arrowRelated Article in JNCI
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© Oxford University Press 2007.

NEWS

NOT GETTING WORSE?

More Clinical Cancer Treatments Judged by Progression-Free Rather Than Overall Survival

Mary Beckman

The first 150 words of the full text of this article appear below.

Cancer research aims to help patients live longer, healthier lives. But waiting for patients to die to determine how well a drug works tries the patience of doctors and researchers. Measuring the effectiveness of a drug by how long it keeps cancer at bay may offer a faster way to find good interventions, but such methods have their own problems.

Known as progression-free survival (PFS) or the related time to progression (TTP), these methods measure the effectiveness of drugs faster than waiting for study participants to die from their cancers. The U.S. Food and Drug Administration has held meetings to discuss the advantages and pitfalls of PFS (sometimes used as an umbrella term for both concepts). Researchers like PFS because studies can be shorter and smaller, making them potentially less costly. While the FDA appreciates the shorter time it takes to rule therapeutics in or out, it warns that researchers . . . [Full Text of this Article]

Cancer at Bay

The Measurement Problem

Works for Some, Not for All


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?

Related Article in JNCI

When You Look Matters: The Effect of Assessment Schedule on Progression-Free Survival
Katherine S. Panageas, Leah Ben-Porat, Maura N. Dickler, Paul B. Chapman, and Deborah Schrag
J Natl Cancer Inst 2007 99: 428-432. [Abstract] [Full Text] [PDF]